CCL19 overexpression
|
Melanoma
|
CCL19 overexpression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
CCL19 overexpression
|
Follicular Lymphoma
|
CCL19 overexpression
|
Follicular Lymphoma
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|